Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
K-RAS ONCOGENE MUTATIONS INDICATE MALIGNANCY IN CYSTIC TUMORS OF THE PANCREAS
Autore:
BARTSCH D; BASTIAN D; BARTH P; SCHUDY A; NIES C; KISKER O; WAGNER HJ; ROTHMUND M;
Indirizzi:
PHILIPPS UNIV MARBURG,DEPT SURG,BALDINGERSTR D-35043 MARBURG GERMANY PHILIPPS UNIV MARBURG,DEPT PATHOL D-35043 MARBURG GERMANY PHILIPPS UNIV MARBURG,DEPT RADIOL D-35043 MARBURG GERMANY
Titolo Testata:
Annals of surgery
fascicolo: 1, volume: 228, anno: 1998,
pagine: 79 - 86
SICI:
0003-4932(1998)228:1<79:KOMIMI>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
FINE-NEEDLE ASPIRATION; MUCINOUS CYSTADENOCARCINOMA; DIFFERENTIAL-DIAGNOSIS; MICROCYSTIC-ADENOMAS; SEROUS CYSTADENOMAS; CODON-12 MUTATIONS; POINT MUTATIONS; NEOPLASMS; ADENOCARCINOMA; CYTOLOGY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
45
Recensione:
Indirizzi per estratti:
Citazione:
D. Bartsch et al., "K-RAS ONCOGENE MUTATIONS INDICATE MALIGNANCY IN CYSTIC TUMORS OF THE PANCREAS", Annals of surgery, 228(1), 1998, pp. 79-86

Abstract

Objective To evaluate clinical parameters, presurgical diagnostic tests, histologic findings, and the presence of K-ras oncogene mutations in cystic tumors of the pancreas to determine which best predict malignancy. Summary Background Data Because presurgical, intraoperative, and final pathologic differentiation is difficult in cystic tumors of the pancreas, it would be a major benefit to identify markers that accurately predict malignancy in these rare tumors. The role of K-ras oncogene mutations as an indicator of malignancy has not been determined inthese tumors. Methods Nineteen patients with cystic tumors of the pancreas were evaluated, including K-ras mutation analysis based on polymerase chain reaction and restriction digestion assays and direct DNA sequencing, to screen for parameters that accurately predict malignancy. Results All malignant cystic pancreatic tumors (five cystadenocarcinomas and three mucin-producing adenocarcinomas) harbored K-ras mutations at codon 12 or 13. K-ras mutations were also detected in the percutaneous fine-needle aspirates of two of these patients. In contrast, none of nine benign cystadenomas or the solid-papillary neoplasm had K-ras mutations. None of the patients with a benign tumor carrying K-ras wild-type sequences developed recurrent disease after a mean follow-upof 50 months. Seven of the 8 malignant cystic pancreatic tumors, but none of the 11 benign tumors, showed dilatation of the main pancreaticduct on computed tomography or endoscopic retrograde cholangiopancreatography. Conclusions K-ras mutation analysis seems to be a powerful tool to determine the malignant potential of cystic pancreatic tumors before and after surgery. Dilatation of the main pancreatic duct on computed tomography or endoscopic retrograde cholangiopancreatography is highly suggestive for malignancy in these rare tumors.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 14:27:44